UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritis

Thursday, December 21, 2017 | Psoriasis , Research and Publications , UCB

UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy in psoriatic arthritis (PsA) signs and symptoms, as well as skin clearance measured by the PASI90 response, compared to placebo at Week 12.

Open in New Window Next Story


You must be logged in to leave a comment.